Publications by authors named "E Cervera-Ceballos"
Introduction: Glycyrrhizin (GA) and its derivative Enoxolone (18β), isolated from the plant, are two potential molecules for treating viral diseases. Both demonstrate to regulate immune system with antiviral and anti-inflammatory activities, with the latter mainly due to modulation of inflammatory cytokines. The aim of this clinical trial was to evaluate the safety and efficacy of a nebulized GA/18β drug for treating COVID-19 patients.
View Article and Find Full Text PDFChronic myeloid leukemia (CML) is a hematologic disorder characterized by the oncogene BCR-ABL1, which encodes an oncoprotein with tyrosine kinase activity. Imatinib, a BCR-ABL1 tyrosine kinase inhibitor, performs exceptionally well with minimal toxicity in CML chemotherapy. According to clinical trials, however, 20-30% of CML patients develop resistance to imatinib.
View Article and Find Full Text PDFIntroduction: Severe acute respiratory syndrome-related coronavirus (SARS-CoV-2) infection is characterised by a viral phase and a severe pro-inflammatory phase. The inhibition of the JAK/STAT pathway limits the pro-inflammatory state in moderate to severe COVID-19.
Methodology: We analysed the data obtained by an observational cohort of patients with SARS-CoV-2 pneumonia treated with ruxolitinib in 22 hospitals of Mexico.
Assessment of measurable residual disease (often referred to as "minimal residual disease") has emerged as a highly sensitive indicator of disease burden during and at the end of treatment and has been correlated with time-to-event outcomes in chronic lymphocytic leukemia. Undetectable-measurable residual disease status at the end of treatment demonstrated independent prognostic significance in chronic lymphocytic leukemia, correlating with favorable progression-free and overall survival with chemoimmunotherapy. Given its utility in evaluating depth of response, determining measurable residual disease status is now a focus of outcomes in chronic lymphocytic leukemia clinical trials.
View Article and Find Full Text PDFArticle Synopsis
- Eccrine porocarcinoma (EPC) is a rare skin tumor, comprising only 0.005-0.01% of all skin tumors, with fewer than 300 reported cases worldwide.
- No cases of EPC in the intergluteal cleft have been documented in English or Spanish literature, making this the first reported instance.
- Treatment primarily involves surgical excision, and while treatment of metastatic EPC is less common (only <10% of cases), this patient has developed metastases and is undergoing chemotherapy with etoposide, vincristine, and carboplatin.